Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Quantification of peripheral whole blood, cell-free plasma and exosome encapsulated mitochondrial DNA copy numbers in patients with atrial fibrillation.

Soltész B, Urbancsek R, Pös O, Hajas O, Forgács IN, Szilágyi E, Nagy-Baló E, Szemes T, Csanádi Z, Nagy B.

J Biotechnol. 2019 Jun 20;299:66-71. doi: 10.1016/j.jbiotec.2019.04.018. Epub 2019 May 4.

PMID:
31063814
2.

Conference report: improving outcomes for gastrointestinal cancer in the UK.

Forgacs I, Ashton R, Allum W, Bowley T, Brown H, Coleman MP, Fitzgerald R, Glynn M, Hiom S, Jones R, Machesney M, Maher J, Pereira SP, Steele R, Veitch A, Wyatt S.

Frontline Gastroenterol. 2018 Jan;9(1):49-61. doi: 10.1136/flgastro-2016-100713. Epub 2016 Jun 14. Review. No abstract available.

3.

Deficiencies in services for acute upper gastrointestinal bleeding.

Lobo AJ, Greenfield SM, Forgacs I.

BMJ. 2015 Sep 11;351:h4774. doi: 10.1136/bmj.h4774. No abstract available.

PMID:
26362313
4.

Use of faecal occult blood tests in symptomatic patients.

Steele R, Forgacs I, McCreanor G, Benton S, Machesney M, Rees C, Halloran SP, Abulafi M, Alsina D.

BMJ. 2015 Aug 11;351:h4256. doi: 10.1136/bmj.h4256. No abstract available.

PMID:
26265582
5.

Perceptions of symptoms and expectations of advanced therapy for Parkinson's disease: preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson's disease (PRO-APD).

Reddy P, Martinez-Martin P, Brown RG, Chaudhuri KR, Lin JP, Selway R, Forgacs I, Ashkan K, Samuel M.

Health Qual Life Outcomes. 2014 Jan 24;12:11. doi: 10.1186/1477-7525-12-11.

6.

Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects.

Reddy P, Martinez-Martin P, Rizos A, Martin A, Faye GC, Forgacs I, Odin P, Antonini A, Chaudhuri KR.

Clin Neuropharmacol. 2012 Sep-Oct;35(5):205-7. doi: 10.1097/WNF.0b013e3182613dea.

PMID:
22821063
7.

Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.

Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K, Mancini F, Canesi M, Odin P, Chaudhuri KR.

Mov Disord. 2009 Jul 30;24(10):1468-74. doi: 10.1002/mds.22596.

PMID:
19425079
8.

Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse.

Maiden L, Takeuchi K, Baur R, Bjarnason I, O'Donohue J, Forgacs I, Chung-Faye G, Sanderson J, Bjarnason I.

Inflamm Bowel Dis. 2008 Oct;14(10):1413-8. doi: 10.1002/ibd.20505.

PMID:
18521900
9.

Overprescribing proton pump inhibitors.

Forgacs I, Loganayagam A.

BMJ. 2008 Jan 5;336(7634):2-3. doi: 10.1136/bmj.39406.449456.BE. No abstract available.

10.

Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.

Chung-Faye G, Hayee B, Maestranzi S, Donaldson N, Forgacs I, Sherwood R.

Inflamm Bowel Dis. 2007 Nov;13(11):1374-8.

PMID:
17577247
11.

Psychological approach to managing irritable bowel syndrome.

Hayee B, Forgacs I.

BMJ. 2007 May 26;334(7603):1105-9. Review. No abstract available.

12.

Private practice--definitely not a zero sum game.

Forgacs I.

J R Soc Med. 2006 Dec;99(12):644. No abstract available.

13.

Unexplained (non-cardiac) chest pain.

Fox M, Forgacs I.

Clin Med (Lond). 2006 Sep-Oct;6(5):445-9. Review. No abstract available.

14.

Gastro-oesophageal reflux disease.

Fox M, Forgacs I.

BMJ. 2006 Jan 14;332(7533):88-93. Review. No abstract available.

15.

Death to all cliches.

Forgacs I.

J R Soc Med. 2005 Dec;98(12):554. No abstract available.

16.

Intestinal infection and irritable bowel syndrome.

Parry S, Forgacs I.

Eur J Gastroenterol Hepatol. 2005 Jan;17(1):5-9. Review.

PMID:
15647632
17.

Whipple's disease presenting with symmetrical panniculitis.

Friedmann AC, Perera GK, Jayaprakasam A, Forgacs I, Salisbury JR, Creamer D.

Br J Dermatol. 2004 Oct;151(4):907-11.

PMID:
15491437
18.

Referee's half-time analysis.

Forgacs I.

BMJ. 2003 Dec 20;327(7429):1474. No abstract available.

19.

Upper gastrointestinal endoscopy performed by nurses: scope for the future?

Smale S, Bjarnason I, Forgacs I, Prasad P, Mukhood M, Wong M, Ng A, Mulcahy HE.

Gut. 2003 Aug;52(8):1090-4.

20.

Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease.

Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I.

Gastroenterology. 2002 Aug;123(2):450-60.

PMID:
12145798
21.

The required number of physicians: is it an optimal figure?

Forgacs I.

Cah Sociol Demogr Med. 2002 Apr-Sep;42(2-3):269-82.

PMID:
12078328
22.

A model for the long-term planning of physician workforce in Hungary.

Forgacs I, Paksy A.

Cah Sociol Demogr Med. 2001 Jul-Dec;41(3-4):313-25.

PMID:
11859637
23.

The effects of a preassessment clinic on nonattendance rates for day-case colonoscopy.

Tibble JA, Forgacs I, Bjarnason I, Przemioslo R.

Endoscopy. 2000 Dec;32(12):963-5.

PMID:
11147945
24.

Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg).

Lister RK, Jolles S, Whittaker S, Black C, Forgacs I, Cramp M, Potter M, Rustin MH.

J Am Acad Dermatol. 2000 Aug;43(2 Pt 2):403-8.

PMID:
10901735
25.

Key developments in gastroenterology.

Forgacs I.

Practitioner. 2000 Apr;244(1609):360-4. Review. No abstract available.

PMID:
10892057
26.

[Medicine and health care].

Forgács I.

Orv Hetil. 1999 Jun 27;140(26):1451-5. Hungarian.

PMID:
10442000
27.

A positive diagnosis for IBS.

Forgacs I.

Practitioner. 1998 Nov;242(1592):794-8. Review. No abstract available.

PMID:
10441894
28.

Caring for and about acute general medicine.

Forgacs I.

BMJ. 1999 Jan 9;318(7176):73-4. No abstract available.

29.

Reduced bone density in patients with inflammatory bowel disease.

Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C.

Gut. 1997 Feb;40(2):228-33.

30.

Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria.

Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I.

Gut. 1996 Mar;38(3):365-75.

31.

Clinical gastroenterology.

Forgacs I.

BMJ. 1995 Jan 14;310(6972):113-6. Review. No abstract available.

32.

Escaping gas: immortality, deflation, and toxic dilation.

Forgacs I.

Lancet. 1994 Dec 3;344(8936):1521. No abstract available.

PMID:
7983949
33.

Introduction to new section - Views and reviews.

Forgacs I.

Gut. 1994 Jun;35(6):732. No abstract available.

34.

Autoimmunity in ulcerative colitis?

Forgacs I.

Lancet. 1993 Mar 6;341(8845):602. No abstract available.

PMID:
8094837
35.

Mitochondrial gene expression in the human gastrointestinal tract.

Macpherson AJ, Mayall TP, Chester KA, Abbasi A, Forgacs I, Malcolm AD, Peters TJ.

J Cell Sci. 1992 Jun;102 ( Pt 2):307-14.

36.

Percutaneous endoscopic gastrostomy.

Forgacs I, Macpherson A, Tibbs C.

BMJ. 1992 May 30;304(6839):1395-6. No abstract available.

37.

Discovery of the gene for familial adenomatous polyposis.

Macpherson AJ, Bjarnason I, Forgacs IC.

BMJ. 1992 Apr 4;304(6831):858-9. No abstract available.

38.

Continuing education and medical schools.

Forgács I.

Med Educ. 1992 Mar;26(2):85-6. No abstract available.

PMID:
1565036
39.

Postgraduate and continuing education in Hungary.

Forgacs I.

Cah Sociol Demogr Med. 1991 Jan-Mar;31(1):5-14. No abstract available.

PMID:
2070268
40.
41.

Oncogenes and gastrointestinal cancer.

Forgacs I.

Gut. 1988 Apr;29(4):417-21. Review. No abstract available.

42.

Gastroenterology.

Forgacs I.

Lancet. 1988 Mar 26;1(8587):708. No abstract available.

PMID:
2895242
43.

Pseudotumour cerebri in a patient with Castleman's disease.

Black DA, Forgacs I, Davies DR, Thompson RP.

Postgrad Med J. 1988 Mar;64(749):217-9.

44.

Abnormal distribution of c-myc oncogene product in familial adenomatous polyposis.

Sundaresan V, Forgacs IC, Wight DG, Wilson B, Evan GI, Watson JV.

J Clin Pathol. 1987 Nov;40(11):1274-81.

45.

Shock news for gall stones.

Forgacs I.

Br Med J (Clin Res Ed). 1987 Sep 26;295(6601):737-8. Review. No abstract available.

46.

Comparison of effects of ingested medium- and long-chain triglyceride on gallbladder volume and release of cholecystokinin and other gut peptides.

Isaacs PE, Ladas S, Forgacs IC, Dowling RH, Ellam SV, Adrian TE, Bloom SR.

Dig Dis Sci. 1987 May;32(5):481-6.

PMID:
3568934
47.

Towards a new health policy in Hungary.

Forgács I, Kokeny M.

Health Policy. 1987;8(2):183-92.

PMID:
10284582
48.

Serious infection in the intensive therapy unit: a 15-year study of bacteraemia.

Forgacs IC, Eykyn SJ, Bradley RD.

Q J Med. 1986 Aug;60(232):773-9.

PMID:
3774960
49.

Outpatient endoscopic survey of smoking and peptic ulcer.

Ainley CC, Forgacs IC, Keeling PW, Thompson RP.

Gut. 1986 Jun;27(6):648-51.

50.

Influence of gallstones and ursodeoxycholic acid therapy on gallbladder emptying.

Forgacs IC, Maisey MN, Murphy GM, Dowling RH.

Gastroenterology. 1984 Aug;87(2):299-307.

PMID:
6329890

Supplemental Content

Loading ...
Support Center